Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Cancer. 2009 Mar;45(4):536-50. doi: 10.1016/j.ejca.2008.11.014. Epub 2008 Dec 27.

The levels of telomere-binding proteins in human tumours and therapeutic implications.

Author information

1
Pharminox Ltd., BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK. humphreys_jenny@yahoo.com

Abstract

Tumours require telomeric integrity to maintain viability, conferred by adequate length of telomeric DNA replenished by telomerase, and binding of telomere-binding proteins (TBPs), thus telomeres have received attention as an anticancer target. Levels of TBPs in tumour tissue may have implications for drug development if they render some cancers relatively more sensitive or resistant to telomere targeted agents. This review gives an overview of the studies examining the levels of TBPs in tumours and discusses possible reasons for differences in the findings, given the interplay between various factors determining telomere stability. Whether cancers with lower levels of TBPs will be more susceptible to therapies targeting telomere maintenance will require clinical trials of these novel therapies.

PMID:
19114299
DOI:
10.1016/j.ejca.2008.11.014
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center